このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Cognition Therapeutics 過去の業績

過去基準チェック /06

Cognition Therapeuticsの収益は年平均-27.6%で減少しているが、Pharmaceuticals業界はdecliningで0.4%年平均の収益となった。

主要情報

-27.6%

収益成長率

83.8%

EPS成長率

Pharmaceuticals 業界の成長	6.0%
収益成長率	n/a
株主資本利益率	-99.7%
ネット・マージン	n/a
前回の決算情報	31 Mar 2024

Recent updates

Is Cognition Therapeutics (NASDAQ:CGTX) In A Good Position To Deliver On Growth Plans?

May 22

Cognition Therapeutics: Approaching Phase 2 Readout In Alzheimer's

Apr 18

Here's Why We're Watching Cognition Therapeutics' (NASDAQ:CGTX) Cash Burn Situation

Nov 30

Is Cognition Therapeutics (NASDAQ:CGTX) In A Good Position To Deliver On Growth Plans?

Aug 15

Cognition Therapeutics (NASDAQ:CGTX) Is In A Good Position To Deliver On Growth Plans

Mar 17

Cognition stock rises 12% on $2.14M grant from NIH for Alzheimer's study

Sep 27

We Think Cognition Therapeutics (NASDAQ:CGTX) Can Afford To Drive Business Growth

Aug 12

Cognition's Alzheimer's candidate demonstrates mechanism of action; shares soar

Aug 05

We're Not Very Worried About Cognition Therapeutics' (NASDAQ:CGTX) Cash Burn Rate

Mar 19

収支内訳

Cognition Therapeutics の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。

収益と収入の歴史

NasdaqGM:CGTX 収益、費用、利益 ( )USD Millions
日付	収益	G+A経費	研究開発費
31 Mar 24	-29	14	42
31 Dec 23	-26	14	37
30 Sep 23	-23	13	32
30 Jun 23	-23	14	29
31 Mar 23	-24	14	29
31 Dec 22	-21	13	30
30 Sep 22	-24	17	29
30 Jun 22	-22	14	25
31 Mar 22	-19	12	21
31 Dec 21	-16	10	19
30 Sep 21	-12	5	16
30 Jun 21	-10	4	16
31 Mar 21	-9	4	14
31 Dec 20	-12	5	13

質の高い収益: CGTXは現在利益が出ていません。

利益率の向上: CGTXは現在利益が出ていません。

フリー・キャッシュフローと収益の比較

過去の収益成長分析

収益動向: CGTXは利益が出ておらず、過去 5 年間で損失は年間27.6%の割合で増加しています。

成長の加速: CGTXの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。

収益対業界: CGTXは利益が出ていないため、過去 1 年間の収益成長をPharmaceuticals業界 ( 19.9% ) と比較することは困難です。

株主資本利益率

高いROE: CGTXは現在利益が出ていないため、自己資本利益率 ( -99.68% ) はマイナスです。

Cognition Therapeutics 過去の業績

過去 基準チェック /06

主要情報

最近の業績更新

Cognition Therapeutics, Inc. to Report Q4, 2023 Results on Mar 26, 2024

Cognition Therapeutics, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Cognition Therapeutics, Inc. to Report Q2, 2022 Results on Aug 09, 2022

Cognition Therapeutics, Inc. to Report Q1, 2022 Results on May 11, 2022

Recent updates

Is Cognition Therapeutics (NASDAQ:CGTX) In A Good Position To Deliver On Growth Plans?

New major risk - Financial position

Cognition Therapeutics, Inc. Completes Enrollment in Phase 2 SHIMmer Study of CT1812 in Mild-to-Moderate Dementia with Lewy Bodies

Cognition Therapeutics, Inc., Annual General Meeting, Jun 07, 2024

Cognition Therapeutics: Approaching Phase 2 Readout In Alzheimer's

Cognition Therapeutics, Inc. to Report Q4, 2023 Results on Mar 26, 2024

Cognition Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $11.499999 million.

Cognition Therapeutics, Inc. Presents Analyses at AD/PD 2024 Correlating Proteomic Findings with Treatment Effect of CT1812 in Alzheimer’s Disease Studies

Here's Why We're Watching Cognition Therapeutics' (NASDAQ:CGTX) Cash Burn Situation

Cognition Therapeutics Completes Enrollment in Phase 2 SHINE Study of CT1812 in Mild-To-Mod Moderate Alzheimer's Disease

Cognition Therapeutics, Inc. Appoints Quang Pham as Board Director

Cognition Therapeutics, Inc. Appoints Quang Pham as Board Director

Cognition Therapeutics, Inc. Presents Complete EEG Findings from SEQUEL Study of CT1812 in Mild-to-Moderate Alzheimer's Disease At CTAD

Is Cognition Therapeutics (NASDAQ:CGTX) In A Good Position To Deliver On Growth Plans?

Price target decreased by 19% to US$6.25

Cognition Therapeutics, Inc. to Report Q2, 2023 Results on Aug 08, 2023

New major risk - Share price stability

Cognition Therapeutics, Inc. and the Alzheimer's Clinical Trials Consortium Initiate First Clinical Site in the Phase 2 Start Study in Early Alzheimer's Disease

Cognition Therapeutics, Inc. Announces Positive Topline Results for CT1812 Phase 2 Sequel Study for Mild-To-Moderate Alzheimer’s Disease

Cognition Therapeutics, Inc. Publishes Clinical Evidence that CT1812 Displaces Aß Oligomers from Binding to Neuronal Synapses in Alzheimer’s Disease

Price target decreased by 26% to US$7.75

Cognition Therapeutics (NASDAQ:CGTX) Is In A Good Position To Deliver On Growth Plans

Price target decreased by 8.7% to US$10.50

Cognition Therapeutics, Inc. Completes Enrollment of CT1812 Phase 2 Sequel Study for Mild-to-Moderate Alzheimer’s Disease

Cognition Therapeutics, Inc. Announces New “Conversations” Podcast Episode on Key Insights from Recent Clinical Trials in Alzheimer’s Disease

Cognition Therapeutics, Inc Presents Scientific Rationale, Clinical Biomarker and Preclinical Data Supporting A Phase 2 Clinical Trial with Ct1812 in Geographic Atrophy Secondary to Dry AMD

Cognition Therapeutics, Inc. Highlights Phase 2 Shimmer Study of Ct1812 in Dementia with Lewy Bodies in Presentation At Ctad

Price target decreased to US$11.50

High number of new and inexperienced directors

Cognition Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $6 million.

Cognition Therapeutics is Recruiting for Lewy Body Dementia Phase 2 SHIMMER Trial in Seventeen Research Sites Across the U.S

Cognition Therapeutics Awarded $2.14 Million in Supplemental Grant Funding from NIA to Support Sequel Clinical Trial

Cognition stock rises 12% on $2.14M grant from NIH for Alzheimer's study

We Think Cognition Therapeutics (NASDAQ:CGTX) Can Afford To Drive Business Growth

Cognition Therapeutics, Inc. Presents New Proteomic Data on Effect of CT1812 Treatment on Normalization of Disrupted Alzheimer's Disease Processes

Cognition's Alzheimer's candidate demonstrates mechanism of action; shares soar

Cognition Therapeutics, Inc. to Report Q2, 2022 Results on Aug 09, 2022

Cognition Therapeutics, Inc. Announces CFO Changes

Cognition Therapeutics, Inc. Doses First Patient with Dementia with Lewy Bodies in Phase 2 Clinical Study of CT1812

Cognition Therapeutics, Inc. to Report Q1, 2022 Results on May 11, 2022

High number of new and inexperienced directors

Cognition Therapeutics, Inc., Annual General Meeting, Jun 10, 2022

We're Not Very Worried About Cognition Therapeutics' (NASDAQ:CGTX) Cash Burn Rate

High number of new and inexperienced directors

収支内訳

収益と収入の歴史

フリー・キャッシュフローと収益の比較

過去の収益成長分析

株主資本利益率

総資産利益率

使用総資本利益率

過去の好業績企業の発掘

過去基準チェック /06